Ioanna Gouni‐Berthold

Lipoprotein(a) Reduction in Persons with Cardiovascular Disease

Sotirios Tsimikas, Ewa Karwatowska‐Prokopczuk, Ioanna Gouni‐Berthold et al. · New England Journal of Medicine · 2020 · 924 citations · Full text

Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk

Michelle L. O’Donoghue, Sergio Fazio, Robert P. Giugliano et al. · Circulation · 2019 · 895 citations · Full text

PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial

Frederick J. Raal, Evan A. Stein, Robert Dufour et al. · The Lancet · 2014 · 734 citations

Metabolic Syndrome, Lipid Disorder, Heterozygous Familial Hypercholesterolaemia +11

EU-Wi<i>d</i>e Cross-Section<i>a</i>l Obser<i>v</i>at<i>i</i>o<i>n</i>al Study of Lipid-Modifying Therapy Use in Se<i>c</i>ondary and Pr<i>i</i>mary Care: the DA VINCI study

Kausik K. Ray, Bart Molemans, W. Marieke Schoonen et al. · European Journal of Preventive Cardiology · 2020 · 699 citations · Full text

Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial

Robert P. Giugliano, Terje R. Pedersen, Jeong-Gun Park et al. · The Lancet · 2017 · 658 citations

Cardiovascular Disease, Pcsk9 Inhibitor Evolocumab, Pharmacology +9